Wolfe starts ‘best-in-class’ Tempus AI with an Outperform

As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Tempus AI (TEM) with an Outperform rating and $60 price target Tempus AI, a diagnostic company that has built a broad and growing menu of diagnostic tests to address clinical needs and amass genetic and phenotypic data, has been “best-in-class in this category as measured by monetization,” the analyst tells investors. The firm expects Tempus to generate a 30% revenue compound annual growth rate through FY28 as it expects more market penetration, more tests/patient, more menu, and more database monetization.